Skip to main content
. 2021 Nov 10;148(10):2673–2680. doi: 10.1007/s00432-021-03779-0

Fig. 2.

Fig. 2

Showing immunoreactivity in cutaneous melanoma for DCD (mainly cytosolic, a), KRT9 (membranous, b), and PIP (mainly nuclear, c)